Enhancing vaccines with immune stimulatory CpG DNA

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 1, 2001, Pages 15-24

  Krieg, A M ^a   Davis, H L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Adjuvant; CpG motif; Innate immunity; Oligodeoxynucleotide; Toll like receptor; Vaccine

Indexed keywords

BACTERIAL ANTIGEN; BETA GALACTOSIDASE; CELL RECEPTOR; DINUCLEOTIDE; DNA; DNA VACCINE; GANGLIOSIDE GD3; GLYCOPROTEIN GP 120; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT; LYSOZYME; OLIGODEOXYNUCLEOTIDE; OVALBUMIN; PARASITE ANTIGEN; TETANUS TOXOID; TUMOR ANTIGEN; VIRUS ANTIGEN;

ANIMAL CELL; ARTICLE; CPG ISLAND; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; METHYLATION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; VERTEBRATE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANIMALS, NEWBORN; CPG ISLANDS; HUMANS; HYPERSENSITIVITY; IMMUNITY, MUCOSAL; INFANT, NEWBORN; MICE; OLIGODEOXYRIBONUCLEOTIDES; VACCINES; VACCINES, DNA;

ANIMALIA; BACTERIA (MICROORGANISMS); VERTEBRATA;

EID: 0035112910     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity
2. CpG motifs in bacterial DNA trigger direct B-cell activation
3. CpG islands as gene markers in the vertebrate nucleus
4. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry
5. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs
6. Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs
7. Innate immunity: Impact on the adaptive immune response
8. Toll-like receptors in the induction of the innate immune response
9. Causing a commotion in the blood: Immunotherapy progresses from bacteria to bacterial DNA
10. A toll-like receptor recognizes bacterial DNA
11. Immune cell activation by bacterial Cpg DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6
12. Macrophages ingest and are activated by bacterial DNA
13. Cpg DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation
14. Cell type-specific activation of mitogen-activated protein kinases by Cpg DNA controls interleukin-12 release from antigen-presenting cells
15. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA
16. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species
17. DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA
18. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA
19. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-Myc and Bcl-xL
20. Activation of human B cells by phosphorothioate oligodeoxynucleotides
21. Mechanism and function of a newly identified CpG DNA motif in human primary B cells
22. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
23. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
24. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA
25. Bacterial Cpg DNA activates dendritic cells in vivo: T helper cell independent cytotoxic T cell responses to soluble proteins
26. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
27. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent
28. CpG DNA and LPS induce distinct patterns of activation in human monocytes
29. Macrophages sense pathogens via DNA motifs: Induction of tumor necrosis factor-α-mediated shock
30. Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T cells to induce IFN-γ production in vitro
31. Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity
32. CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of IκBα and IκBβ and sustained activation of nuclear factor-κ B/c-Rel
33. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
34. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants
35. DNA as an adjuvant: Capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen
36. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
37. CpG DNA induces stronger immune responses with less toxicity than other adjuvants
38. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
39. Adjuvants that enhance priming of cytotoxic T cells to a Kb-restricted epitope processed from exogenous but not endogenous hepatitis B surface antigen
40. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
41. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins
42. In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides
43. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M tuberculosis
44. Dual function of Drosophila cells as APCs for naive CD8+ T cells: Implications for tumor immunotherapy
45. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
46. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor
47. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
48. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans
49. Mammalian granulocyte-macrophage colony-stimulating factor and some CpG motifs have an effect on the immunogenicity of DNA and subunit vaccines in fish
50. Protective immunity to VHS in rainbow trout (Oncorhynchus mykiss, Walbaum) following DNA vaccination
51. Use of CpG DNA for enhancing specific immune responses
52. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates
53. Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide
54. Synthetic oligodeoxynucleotide containing CpG motif induces an anti-polysaccharide type 1-like immune response after immunization of mice with Haemophilus influenzae type b conjugate vaccine
55. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies
56. CpG oligodeoxynucleotides overcome the unresponsiveness of neonatal B cells to stimulation with the thymus-independent stimuli anti-IgM and TNP-Ficoll
57. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice
58. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants
59. CpG DNA is an effective oral adjuvant to protein antigens in mice
60. Immunostimulatory DNA is a potent mucosal adjuvant
61. Antipeptide antibody responses following intranasal immunization: Effectiveness of mucosal adjuvants
62. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice
63. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming
64. DNA vaccines
65. Contribution of CpG motifs to the immunogenicity of DNA vaccines
66. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
67. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses
68. Immunoadjuvant action of plasmid DNA in liposomes
69. Evaluation of the protective efficacy of rabies DNA vaccine in mice using an intracerebral challenge model
70. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons
71. Immuno-stimulatory effects of bacterial-derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations
72. Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid
73. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: A comparison of vaccine formulation, route, and method of administration
74. Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides
75. Isoforms of the major allergen of birch pollen induce different immune responses after genetic immunization
76. Effective DNA vaccination against listeriosis by prime/boost inoculation with the gene gun
77. Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA
78. The role of CpG dinucleotides in DNA vaccines
79. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
80. Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection
81. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
82. Inhibition of IgE antibody formation by plasmid DNA immunization is mediated by both CD4+ and CD8+ T cells
83. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma
84. CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism
85. Synthetic oligodeoxynucleotides inhibit IgE induction in human lymphocytes
86. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice
87. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides
88. Immunostimulatory oligodeoxynucleotide induces TH1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice
89. Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen
90. Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen
91. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma
92. Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes
93. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution
94. CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine: Preliminary results of phase I trial with CpG ODN 7909
95. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines
96. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity
97. CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi
98. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
99. Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines
100. CpG motifs as immune adjuvants
101. Immunostimulatory sequence oligodeoxynucleotide: A novel mucosal adjuvant
102. Immunostimulatory-sequence DNA is an effective mucosal adjuvant